Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their collaboration with European organizations to develop digital capabilities, and the need for better access, investment in manufacturing and increased collaboration in preclinical research.
The past two years have improved the level of trust, responsibility, and capacity to rapidly accomplish incredible medical feats. The general public realizes that [the pharma industry] is part of the solution and a necessary entity to provide real solutions
